- Home
- AVIR vs CCCC Comparison
AVIR vs CCCC Comparison
Compare AVIR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | CCCC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 404.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVIR | CCCC |
|---|---|---|
| Price | $5.84 | $3.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $12.20 |
| AVG Volume (30 Days) | 211.4K | ★ 2.2M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $2.78 | $1.69 |
| 52 Week High | $6.45 | $5.17 |
Technical Indicators
Market Signals| Indicator | AVIR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 43.81 |
| Support Level | $5.13 | $3.40 |
| Resistance Level | $6.37 | $3.91 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 94.70 | 9.76 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.